{
  "drug_name": "Andexanet_alfa",
  "url": "https://wikem.org/wiki/Andexanet_alfa",
  "scraped_at": "2026-01-10T07:47:35.893924",
  "sections": {
    "Administration": {
      "text": "Type: factor Xa inhibitor reversal, antidote\nDosage Forms: solution reconstituted, 100 mg per vial\nRoutes of Administration: IV\nCommon Trade Names: Andexxa",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Determined_by_last_dose,_type_of_factor_Xa_inhibitor,_and_dose_of_inhibitor": {
          "text": "Last dose >8 hours ago\nLow dose\nLast dose <8 hours or unknown\nApixaban\n<5 mg: Low dose\n>5 mg/unknown: High dose\nRivaroxaban\n<10 mg: Low dose\n>10 mg/unknown: High dose",
          "tables": []
        },
        "Low_Dose": {
          "text": "400\nmg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by\n4\nmg/minute for up to 120 minutes",
          "tables": []
        },
        "High_Dose": {
          "text": "800\nmg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by\n8\nmg/minute for up to 120 minutes",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Apixaban",
          "url": "https://wikem.org/wiki/Apixaban"
        },
        {
          "text": "Rivaroxaban",
          "url": "https://wikem.org/wiki/Rivaroxaban"
        }
      ]
    },
    "Determined_by_last_dose,_type_of_factor_Xa_inhibitor,_and_dose_of_inhibitor": {
      "text": "Last dose >8 hours ago\nLow dose\nLast dose <8 hours or unknown\nApixaban\n<5 mg: Low dose\n>5 mg/unknown: High dose\nRivaroxaban\n<10 mg: Low dose\n>10 mg/unknown: High dose",
      "subsections": {
        "Low_Dose": {
          "text": "400\nmg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by\n4\nmg/minute for up to 120 minutes",
          "tables": []
        },
        "High_Dose": {
          "text": "800\nmg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by\n8\nmg/minute for up to 120 minutes",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Apixaban",
          "url": "https://wikem.org/wiki/Apixaban"
        },
        {
          "text": "Rivaroxaban",
          "url": "https://wikem.org/wiki/Rivaroxaban"
        }
      ]
    },
    "Low_Dose": {
      "text": "400\nmg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by\n4\nmg/minute for up to 120 minutes",
      "subsections": {
        "High_Dose": {
          "text": "800\nmg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by\n8\nmg/minute for up to 120 minutes",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "High_Dose": {
      "text": "800\nmg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by\n8\nmg/minute for up to 120 minutes",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "",
      "subsections": {
        "Pregnancy_Rating": {
          "text": "not known",
          "tables": []
        },
        "Lactation_risk": {
          "text": "not known",
          "tables": []
        },
        "Renal_Dosing": {
          "text": "None",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "None",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Pregnancy_Rating": {
      "text": "not known",
      "subsections": {
        "Lactation_risk": {
          "text": "not known",
          "tables": []
        },
        "Renal_Dosing": {
          "text": "None",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "None",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Lactation_risk": {
      "text": "not known",
      "subsections": {
        "Renal_Dosing": {
          "text": "None",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "None",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Renal_Dosing": {
      "text": "None",
      "subsections": {
        "Hepatic_Dosing": {
          "text": "None",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hepatic_Dosing": {
      "text": "None",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy to class/drug",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "Arterial and venous thromboembolism\nDVT\n(6%)\nIschemic stroke\n(5%)\nMyocardial infarction\n(3%)\nPulmonary embolism\n(3%)\nAcute Respiratory failure (1%)\nCardiac arrest\nSudden death",
          "tables": []
        },
        "Common": {
          "text": "Infusion site reaction\nUTI (5%)\nPneumonia (5%)",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "DVT",
          "url": "https://wikem.org/wiki/DVT"
        },
        {
          "text": "Ischemic stroke",
          "url": "https://wikem.org/wiki/Ischemic_stroke"
        },
        {
          "text": "Myocardial infarction",
          "url": "https://wikem.org/wiki/Myocardial_infarction"
        },
        {
          "text": "Pulmonary embolism",
          "url": "https://wikem.org/wiki/Pulmonary_embolism"
        },
        {
          "text": "Cardiac arrest",
          "url": "https://wikem.org/wiki/Cardiac_arrest"
        }
      ]
    },
    "Serious": {
      "text": "Arterial and venous thromboembolism\nDVT\n(6%)\nIschemic stroke\n(5%)\nMyocardial infarction\n(3%)\nPulmonary embolism\n(3%)\nAcute Respiratory failure (1%)\nCardiac arrest\nSudden death",
      "subsections": {
        "Common": {
          "text": "Infusion site reaction\nUTI (5%)\nPneumonia (5%)",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "DVT",
          "url": "https://wikem.org/wiki/DVT"
        },
        {
          "text": "Ischemic stroke",
          "url": "https://wikem.org/wiki/Ischemic_stroke"
        },
        {
          "text": "Myocardial infarction",
          "url": "https://wikem.org/wiki/Myocardial_infarction"
        },
        {
          "text": "Pulmonary embolism",
          "url": "https://wikem.org/wiki/Pulmonary_embolism"
        },
        {
          "text": "Cardiac arrest",
          "url": "https://wikem.org/wiki/Cardiac_arrest"
        }
      ]
    },
    "Common": {
      "text": "Infusion site reaction\nUTI (5%)\nPneumonia (5%)",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 5 to 7 hours",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Mechanism_of_Action": {
      "text": "Binds and sequesters factor Xa inhibitors\nInhibits the activity of the Tissue Factor Pathway Inhibitor (TFPI), increasing tissue factor-initiated thrombin generation",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Comments": {
      "text": "FDA approved in May 2018, limited availability June 2018 with broader commercial launch in early 2019\nCost, $3,300 per 100 mg vial",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "See_Also": {
      "text": "Apixaban\nRivaroxaban\nAnticoagulant reversal for life-threatening bleeds\nRivaroxaban reversal",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Apixaban",
          "url": "https://wikem.org/wiki/Apixaban"
        },
        {
          "text": "Rivaroxaban",
          "url": "https://wikem.org/wiki/Rivaroxaban"
        },
        {
          "text": "Anticoagulant reversal for life-threatening bleeds",
          "url": "https://wikem.org/wiki/Anticoagulant_reversal_for_life-threatening_bleeds"
        },
        {
          "text": "Rivaroxaban reversal",
          "url": "https://wikem.org/wiki/Rivaroxaban_reversal"
        }
      ]
    },
    "References": {
      "text": "Lu, G., DeGuzman, F. R., Hollenbach, S. J., Karbarz, M. J., Abe, K., Lee, G., … Sinha, U. (2013). A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature Medicine, 19(4), 446–451.\nAndexxa (andexanet alfa) [prescribing information]. South San Francisco, CA: Portola Pharmaceuticals, Inc; May 2018",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}